Citations

Clear

168 citation(s) found for "Perlmutter, J".

Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) (S27.004)
Comella, Cynthia , Barbano, Richard L. , Goetz, Christopher G. , Galpern, Wendy R., Marsh, Laura , McDonald, William M. , Reich, Stephen G. , Rosen, Ami, Severt, William, Waliczek, Tracy, Stebbins, Glenn T. , Perlmutter, Joel S. , Jinnah, H. A. , Adler, Charles H. , Factor, Stewart Alan , Fox, Susan H. , Jankovic, Joseph J. , Rodriguez, Ramon L.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s27.004 Get It

Reliability of the Severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) (S15.001)
Comella, Cynthia , Goetz, Christopher G. , Barbano, Richard L. , Severt, William, Reich, Stephen G. , Galpern, Wendy R., Rosen, Ami, Stebbins, Glenn T. , Perlmutter, Joel S. , Jinnah, H. A. , Factor, Stewart Alan , Adler, Charles H. , Fox, Susan H. , Jankovic, Joseph J. , Rodriguez, Ramon L. , Stover, Natividad

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.s15.001 Get It

Artificial Intelligence Enabled ECG Interpretation Informs Outcomes after Autologous Transplantation for Multiple Myeloma
Attia, Itzhak Zachi, Greason, Grace , Lahoud, Oscar , Schaffer, Wendy, Liu, Jennifer , Landau, Heather , Friedman, Paul A. , Kosmidou, Ioanna , Lahoud, Oscar B , Shaffer, Brian C. , Attia, Itzhak Zachi, Chinapen, Stephanie , Brown, Samantha , Chung, David J , López-Jiménez, Francisco , Giralt, Sergio , Shah, Gunjan L. , Usmani, Saad Z. , Gersh, Bernard J. , Noseworthy, Peter A.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4965-4965

10.1182/blood-2023-184725 Get It

High dose chemotherapy followed by autologous hematopoietic cell transplantation (auto HCT) is a standard therapy for patients with plasma cell disorders (PCD). A barrier to improving candidate selection for auto HCT is appraisal of risk for transplant related complications. Electrocardiography (ECG) is a standard pre-HCT test to evaluate the potential for arrhythmia and structural heart disease. We hypothesized that an artificial intelligence (AI) based interpretation of ECG waveform data (AI-ECG) could enhance risk prediction for cardiac-specific and other outcomes following auto HCT for patients with PCD. To test this hypothesis, we used several AI-ECG tools developed using a deep-learning based approach that were trained to predict comorbidity (Attia et al, Lancet 2019 & Grogan et al, Mayo Clin Proc 2021). Model outputs include a scaled prediction value indicating increasing risk for atrial fibrillation/flutter (AF), reduced ejection fraction (EF), or cardiac amyloidosis. We evaluated this tool in 9,225 ECGs obtained from 849 patients (median 6 ECGs/patient, inter-quartile range: 3-12) who underwent first or subsequent auto HCT at Memorial Sloan Kettering Cancer Center between 2016-2022 and who had a diagnosis of multiple myeloma (N = 810), amyloidosis (N = 37), or other PCD (N = 2). The endpoints were to determine whether baseline AI-ECG prediction of AF risk correlated with peri-transplant AF events, and to explore whether model outputs correlated with survival and other cardiac clinical outcomes. The mean age of patients was 61.0 years (range 23.7 - 81.2) and median follow up was 2.7 years post auto HCT. Contributing cardiovascular risk factors included a prior history of AF (N = 101, 11.9%), coronary or cerebrovascular disease (N = 95, 11.2%), and diabetes mellitus (N = 98, 11.5%). Reduced dose melphalan (< 200 mg/m 2) was administered in 26%. The HCT-comorbidity index (HCT-CI) was high risk (≥3) in 52.7%. The one-year overall survival and progression-free survival in the whole cohort was 94% (95% confidence interval (95% CI): 92 - 95%) and 86% (84 - 89%), respectively. Among patients not in AF at pre HCT evaluation, the 90-day cumulative incidence of AF was 5.6% (4.2 - 7.3%). In univariable competing risk regression, baseline pre HCT AI-ECG appraisal of AF risk was strongly correlated with incidence AF in patients who were in sinus rhythm before HCT (hazard ratio (HR): 25.1, 95% CI: 11.7 - 53.7, p < 0.001). In a multivariable model adjusting for patient age and HCT-CI, AI-ECG AF predicted risk remained associated with incidence of post HCT AF (HR: 13.4, 95% CI: 5.9 - 30.4, p < 0.001). Considering a decision threshold identified during original model training, AI-ECG predicted AF events with an accuracy of 75% (Mcnemar's p < 2 x 10 -16). The precision, recall, and F1-score were 0.94, 0.77, and 0.85, respectively. AI-ECG predicted age correlated highly with actual patient age (Spearman rho = 0.59, p < 2 x 10 -16). Amyloid risk scores were highly correlated with a known clinical history of amyloidosis (median 0.45 versus 0.05, Wilcoxon rank-sum p < 0.001). Patients with EF < 50% had greater prediction scores for cardiomyopathy compared to patients with normal EF (median 0.23 versus 0.01, Wilcoxon rank-sum p <0.001). In univariable analysis, increasing AI-ECG predicted age (HR 1.02, CI: 1.003 - 1.04, p = 0.02) and predicted AF risk score (HR: 3.2, CI: 1.4 - 7.2, p = 0.006) were associated with risk for death, whereas predicted amyloid score and predicted low EF were not associated with decreased survival. In multivariable analysis of all patients that considered patient age, hematopoietic comorbidity index, and remission status at HCT, increasing predicted AF score trended towards association with increased risk for death (HR: 2.3, 95%CI: 1.0 - 5.5, p = 0.059). Predicted AF score correlated highly with the HCT-CI and patient age. Finally, we examined whether risk prediction for low EF correlated with peri-HCT fluid overload (FO) defined by absolute weight gain. The incidence of ≥ 10% weight gain (grade 2 FO) and ≥ 20% weight gain (grade 3 FO) at 180 days post HCT was 7.4% (95% CI: 5.8%, 9.3%) and 1.0% (95% CI: 0.5%, 1.8%), respectively. Predicted low EF was not associated with development of either grade 2 or grade 3 FO in this population. In summary, AI-ECG predicts episodes of AF in patients undergoing auto HCT for PCD and may augment transplant risk appraisal when considered in conjunction with other measures of comorbidity.
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson, James N. , Villa, Diego , Chapani, Parv , Li, Shaoying , Medeiros, L. Jeffrey , Wang, Michael , Cohen, Jonathon B. , Churnetski, Michael C. , Hill, Brian T. , Hernandez‐Ilizaliturri, Francisco J. , Kothari, Shalin , Bast, Martin, Fenske, Timothy S. , Gari, Swapna Narayana Rao, Maddocks, Kami J. , Bachanová, Veronika , Kolla, Bhaskar , Donovan, Alexandra M., Wagner‐Johnston, Nina D. , Messmer, Marcus , Anderson, Jennifer K., Reddy, Nishitha , Glenn, Martha, Inwards, David J. , Ristow, Kay M., Rajguru, Saurabh, Evens, Andrew M. , Klein, Andreas K. , Umyarova, Elvira , Pulluri, Bhargavi , Amengual, Jennifer E. , Diefenbach, Catherine , Fisher, Richard I., Villa, Diego , Gerrie, Alina S , Chapani, Parv , Li, Shaoying , Medeiros, L Jeffrey , Wang, Michael L , Sawalha, Yazeed , Vose, Julie , Bond, David A , Kolla, Bhaskar , Lansigan, Frederick , Wagner-Johnston, Nina , Messmer, Marcus , Mehta, Amitkumar , Ristow, Kay, Karmali, Reem , Caimi, Paolo F , Evens, Andrew M , Amengual, Jennifer E , Bachanova, Veronika , Diefenbach, Catherine S , Handorf, Elizabeth A. , Gerrie, Alina S. , Sawalha, Yazeed , Vose, Julie M. , Bond, David A. , Chavez, Julio C , Shah, Bijal , Lansigan, Frederick , Burns, Timothy Francis , Mehta, Amitkumar , Kovach, Alexandra E. , Landsburg, Daniel J. , Karmali, Reem , Kaplan, Jason , Caimi, Paolo F. , Lue, Jennifer Kimberly , Barta, Stefan K

Mayo Clinic

Blood Advances | October 24, 2023 | Volume: 7 | Issue: 24 | Pages: 7393-7401

10.1182/bloodadvances.2023010757 | PMID 37874912 Get It

Abstract Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Desai, Sanjal H. , Evens, Andrew M. , Šýkorová, Alice , Bachanová, Veronika , Goyal, Gaurav , Dorritie, Kathleen , Azzi, Jacues, Kenkre, Vaishalee P. , Chang, Cheryl , Michalka, Jozef , Ansell, Stephen M. , Fusco, Brendon , Hatic, Haris, Saba, Raya , Harris, Elyse I., Wagner‐Johnston, Nina D. , Arai, Sally , Nowakowski, Grzegorz S. , Móciková, Heidi , Jagadeesh, Deepa , Blum, Kristie A. , Diefenbach, Catherine , Iyengar, Siddharth , Rappazzo, Katherine , Choi, Yun Young , Advani, Ranjana H. , Micallef, Ivana N. , Evens, Andrew M , Goyal, Guarav , Dorritie, Kathleen , Sumransub, Nuttavut , Ibrahim, Uroosa , Wagner-Johnston, Nina , Arai, Sally , Mocikova, Heidi , Prochazka, Vit , Micallef, Ivana, Bachanova, Veronika , Advani, Ranjana H , Desai, Sanjal , Diefenbach, Catherine S , Spinner, Michael A. , Kahl, Brad S. , Shah, Harsh , Baidoun, Firas , Procházka, Vít

Mayo Clinic

Blood Advances | September 20, 2023 | Volume: 7 | Issue: 23 | Pages: 7295-7303

10.1182/bloodadvances.2023011205 | PMID 37729621 Get It

Abstract In the pre–novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Page, David B. , Broeckx, Glenn , Jahangir, Chowdhury Arif , Verbandt, Sara , Gupta, Rajarsi , Thagaard, Jeppe , Khiroya, Reena, Kos, Zuzana , Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Bouchmaa, Najat , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Ely, Scott , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hardas, Alexandros , Hartman, Johan , Hewitt, Stephen M. , Hida, Akira I. , Husain, Zaheed, Hytopoulos, Evangelos, Irshad, Sheeba , Janssen, Emiel A. M., Kahila, Mohamed, Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Durga, Kharidehal, Khramtsov, Andrey , Kirtani, Pawan, Korski, Konstanty, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Michiels, Stefan, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Salto‐Tellez, Manuel , Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Sughayer, Maher A. , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Teuwen, Jonas, Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Laak, Jeroen van der , Verghese, Gregory , Viale, Giuseppe , Vieth, Michael, Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Yuan, Yinyin, Bartlett, John Mark Seaverns, Loibl, Sibylle , Loi, Sherene , Salgado, Roberto , Stovgaard, Elisabeth Specht , Symmans, W. Fraser , Kahila, Mohamed M. , Gupta, Rajarsi R , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Chardas, Alexandros , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Reis-Filho, Jorge S , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Symmans, W Fraser , Lennerz, Jochen , Loi, Sherene , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , AbdulJabbar, Khalid , Aktürk, Güray , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil, Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Gallagher, William M. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Kovács, Anikó , Lerousseau, Marvin , Ly, Amy , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rahman, Arman , Rajpoot, Nasir , Rapoport, Bernardo L. , Reis‐Filho, Jorge S. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sur, Daniel Genel , Tran, William T, Diest, P. J. van , Yuan, Yinyin , Adams, Sylvia , Bartlett, John M.S. , Denkert, Carsten , Savas, Peter Stephen

Mayo Clinic

The Journal of Pathology | August 23, 2023 | Volume: 260 | Issue: 5 | Pages: 514-532

10.1002/path.6165 | PMID 37608771 Get It

Abstract Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector‐based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well‐described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Thagaard, Jeppe , Broeckx, Glenn , Page, David B. , Jahangir, Chowdhury Arif , Verbandt, Sara , Kos, Zuzana , Gupta, Rajarsi , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Balslev, Eva , Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Bouchmaa, Najat , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Dahl, Anders Bjorholm , Portela, Flávio Luis Dantas , Deman, Frederik , Hansen, Johan Doré, Dudgeon, Sarah , Ebstrup, Thomas, Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hauberg, Søren , Hewitt, Stephen M. , Hida, Akira I. , Husain, Zaheed, Hytopoulos, Evangelos, Irshad, Sheeba , Janssen, Emiel A. M., Kahila, Mohamed M. , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Durga, Kharidehal, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Mittal, Shachi , Moore, David A. , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Penault‐Llorca, Frédérique, Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Roslind, Anne, Salto‐Tellez, Manuel , Scott, Ely, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Sughayer, Maher A. , Fineberg, Susan , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Laak, Jeroen van der , Verghese, Gregory , Viale, Giuseppe , Vieth, Michael, Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Zin, Reena Md, Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Salgado, Roberto , Stovgaard, Elisabeth Specht , Symmans, W. Fraser , Acs, Balazs , Chardas, Alexandros , Dantas Portela, Flavio Luis , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Kataoka, Tatsuki R , Rau, Tilman T , Reis-Filho, Jorge S , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Symmans, W Fraser , Lennerz, Jochen , Loi, Sherene , Hartman, Johan , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , AbdulJabbar, Khalid , Aktürk, Güray , Almeida, Jonas S. , Amgad, Mohamed T. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Gallagher, William M. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Kovács, Anikó , Lerousseau, Marvin , Ly, Amy , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rahman, Arman , Rajpoot, Nasir , Rapoport, Bernardo L. , Reis‐Filho, Jorge S. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sur, Daniel Genel , Teuwen, Jonas , Tran, William T, Diest, P. J. van , Yuan, Yinyin , Adams, Sylvia , Denkert, Carsten , Savas, Peter Stephen

Mayo Clinic

The Journal of Pathology | August 23, 2023 | Volume: 260 | Issue: 5 | Pages: 498-513

10.1002/path.6155 | PMID 37608772 Get It

AbstractThe clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen receptor, progesterone receptor, and HER2‐negative) breast cancer and HER2‐positive breast cancer. How computational assessments of TILs might complement manual TIL assessment in trial and daily practices is currently debated. Recent efforts to use machine learning (ML) to automatically evaluate TILs have shown promising results. We review state‐of‐the‐art approaches and identify pitfalls and challenges of automated TIL evaluation by studying the root cause of ML discordances in comparison to manual TIL quantification. We categorize our findings into four main topics: (1) technical slide issues, (2) ML and image analysis aspects, (3) data challenges, and (4) validation issues. The main reason for discordant assessments is the inclusion of false‐positive areas or cells identified by performance on certain tissue patterns or design choices in the computational implementation. To aid the adoption of ML for TIL assessment, we provide an in‐depth discussion of ML and image analysis, including validation issues that need to be considered before reliable computational reporting of TILs can be incorporated into the trial and routine clinical management of patients with triple‐negative breast cancer. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)
Raetz, Elizabeth A. , Teachey, David T. , Liu, Xiaowei , Norris, Robin E. , Denic, Kristina Z., Evensen, Nikki A. , Gore, Lia , Fox, Elizabeth , Loh, Mignon L. , Weigel, Brenda J. , Carroll, William L. , Norris, Robin E , Reid, Joel, Evensen, Nikki A , Gore, Lia , Loh, Mignon L , Minard, Charles G. , Reid, Joel M.

Mayo Clinic

Pediatric Blood & Cancer | August 8, 2023 | Volume: 70 | Issue: 11 | Pages: No page available

10.1002/pbc.30609 | PMID 37553297 Get It

Abstract Background Cyclin D has been shown to play an essential role in acute lymphoblastic leukemia (ALL) initiation and progression, providing rationale for targeting the CDK4/6‐cyclin D complex that regulates cell cycle progression. Procedure The Children's Oncology Group AINV18P1 phase 1 trial evaluated the CDK4/6 inhibitor, palbociclib, in combination with standard four‐drug re‐induction chemotherapy in children and young adults with relapsed/refractory B‐ and T‐cell lymphoblastic leukemia (ALL) and lymphoma. Palbociclib (50 mg/m 2 /dose) was administered orally once daily for 21 consecutive days, first as a single agent (Days 1–3) and subsequently combined with re‐induction chemotherapy. This two‐part study was designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), followed by an expansion pharmacokinetic cohort. Results Twelve heavily pretreated patients enrolled, all of whom were evaluable for toxicity. One dose‐limiting hematologic toxicity (DLT) occurred at the starting dose of 50 mg/m 2 /dose orally for 21 days. No additional DLTs were observed in the dose determination or pharmacokinetic expansion cohorts, and overall rates of grade 3/4 nonhematologic toxicities were comparable to those observed with the chemotherapy platform alone. Five complete responses were observed, two among four patients with T‐ALL and three among seven patients with B‐ALL. Pharmacokinetic studies showed similar profiles with both liquid and capsule formulations of palbociclib. Conclusions Palbociclib in combination with re‐induction chemotherapy was well tolerated with a RP2D of 50 mg/m 2 /day for 21 days. Complete responses were observed among heavily pretreated patients.
Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
King, Sontoria D. , Veliginti, Swathi , Brouwers, Martijn C.G.J. , Ren, Zhewen , Zheng, Wei , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Shu, Xiao‐Ou , Arslan, Alan A. , Freeman, Laura E. Beane , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Haiman, Christopher A. , Visvanathan, Kala , White, Emily , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward L. , Hackert, Thilo , Hassan, Manal M. , Kurtz, Robert C. , Lee, I‐Min , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wentzensen, Nicolas , Yu, Kai , Wolpin, Brian M. , Li, Donghui , Patel, Alpa V. , Peters, Ulrike , Ríboli, Elio , Zhong, Jun, Antwi, Samuel O. , Zhong, Jun , Setiawan, Veronica W , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Giles, Graham G , Goodman, Phyllis J , Haiman, Christopher A , Kogevinas, Manolis , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Visvanathan, Kala , White, Emily , Albanes, Demetrius , Andreotti, Gabriella , Babic, Ana , Berndt, Sonja I , Brais, Lauren K , Brennan, Paul , Buring, Julie E , Chaffee, Kari G. , Bamlet, William R , Chanock, Stephen Jacob , Fuchs, Charles S , Gaziano, J Michael , Giovannucci, Edward L , Hackert, Thilo , Hassan, Manal M , Katzke, Verena , Kurtz, Robert C , Lee, I-Min , Malats, Nuria , Murphy, Neil , Oberg, Ann L , Orlow, Irene , Porta, Miquel , Real, Francisco X , Rothman, Nathaniel , Sesso, Howard D , Silverman, Debra T. , Thompson, Ian M , Wactawski-Wende, Jean , Wang, Xiaoliang , Wentzensen, Nicolas , Yu, Herbert , Zeleniuch-Jacquotte, Anne , Yu, Kai , Wolpin, Brian M , Duell, Eric J , Li, Donghui , Hung, Rayjean J , Perdomo, Sandra , McCullough, Marjorie L , Freedman, Neal D , Patel, Alpa V , Peters, Ulrike , Riboli, Elio , Sund, Malin , Tjønneland, Anne , Zhong, Jun , Van Den Eeden, Stephen K , Kraft, Peter , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Stolzenberg-Solomon, Rachael , Antwi, Samuel O , Arslan, Alan A , Shu, Xiao-Ou , Zheng, Wei , Wilkens, Lynne R , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Albanes, Demetrius , Rabe, Kari G. , Bamlet, William R. , Malats, Núria , Murphy, Neil , Orlow, Irene , Real, Francisco X. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Hung, Rayjean J. , McCullough, Marjorie L. , Freedman, Neal D. , Sund, Malin , Tjønneland, Anne , Kraft, Peter , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 24, 2023 | Volume: 32 | Issue: 9 | Pages: 1265-1269

10.1158/1055-9965.epi-23-0453 | PMID 37351909 Get It

Abstract Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer. Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for pancreatic cancer. Methods: Data from genome-wide association studies (GWAS) within the Pancreatic Cancer Cohort Consortium (PanScan; cases n = 5,090, controls n = 8,733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n = 4,163, controls n = 3,792) were analyzed. We used data on 68 genetic variants with four different MR methods [inverse variance weighting (IVW), MR-Egger, simple median, and penalized weighted median] separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and pancreatic cancer risk, using logistic regression to calculate ORs and 95% confidence intervals (CI), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and pancreatic cancer risk in the PanScan or PanC4 samples [e.g., PanScan, IVW OR, 1.04; 95% confidence interval (CI), 0.88–1.22; MR-Egger OR, 0.89; 95% CI, 0.65–1.21; PanC4, IVW OR, 1.07; 95% CI, 0.90–1.27; MR-Egger OR, 0.93; 95% CI, 0.67–1.28]. None of the four MR methods indicated an association between genetically predicted NAFLD and pancreatic cancer risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with pancreatic cancer risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and pancreatic cancer might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and pancreatic cancer.
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials
Hillman, Shauna L., Jatoi, Aminah , Perlmutter, Jane , Mandrekar, Sumithra J. , Strand, Carrie , George, Suzanne

Mayo Clinic

JAMA Oncology | June 23, 2023 | Volume: 9 | Issue: 8 | Pages: 1041

10.1001/jamaoncol.2023.1648 | PMID 37347469 Get It

Importance Patient withdrawal of consent from a cancer clinical trial is defined as a patient’s volitional cessation of participation in all matters related to a trial. It can undermine the trial’s purpose, make the original sample size and power calculations irrelevant, introduce bias between trial arms, and prolong the time to trial completion. Objective To report rates of and baseline factors associated with withdrawal of consent among patients in cancer clinical trials. Design, Setting, and Participants This multisite observational cohort study was conducted through the Alliance for Clinical Trials in Oncology. Patient withdrawal was defined as a patient’s voluntary termination of consent to participate anytime during trial conduct. Baseline patient- and trial-based factors were investigated for their associations with patient withdrawal within the first 2 years using logistic regression models. All patients who participated in cancer therapeutic clinical trials conducted within the Alliance for Clinical Trials in Oncology from 2013 through 2019 were included. The data lock date was January 23, 2022. Main Outcomes and Measures The percentage of patients who withdrew consent in 2 years and factors associated with withdrawal of consent. Results A total of 11 993 patients (median age, 62 years; 67% female) from 58 trials were included. Within 2 years, 1060 patients (9%) withdrew from their respective trials. Two-year rates of withdrawal were 5.7%, 7.6%, 8.5%, 7.8%, 8.4%, 9.5%, and 9.8% for each of the respective years from 2013 through 2019. In multivariable analyses, Hispanic ethnicity (odds ratio [OR], 1.67; 95% CI, 1.30-2.15; P < .001), randomized design with placebo (OR, 1.64; 95% CI, 1.38-1.94; P < .001), and patient age 75 years and older (OR, 1.39; 95% CI, 1.12-1.72; P = .003) were associated with higher likelihood of withdrawal by 2 years. Use of radiation was associated with patient retention (OR, 0.68; 95% CI, 0.54-0.86; P = .001). Conclusions and Relevance In this cohort study, rates of withdrawal of consent were less than 10% and appeared consistent over time. Factors that are associated with withdrawal of consent should be considered when designing trials and should be further studied to learn how they can be favorably modified.